Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778415 | 0.88 | CCR2 (0.64) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1779036 | 0.81 | CCR2 (0.49) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1778054 | 0.80 | CHRM4 (0.49) | CCR2KCNH2CYP3A4CYP2D6DRD2 | |
| SCHEMBL1778727 | 0.78 | CCR2 (0.61) | CCR2KCNH2CYP3A4CYP2D6DRD2 | |
| SCHEMBL1778729 | 0.78 | CCR2 (0.61) | CCR2KCNH2CYP3A4CYP2D6DRD2 | |
| SCHEMBL20234319 | 0.78 | HRH3 (0.45) | DRD4 | |
| SCHEMBL12666610 | 0.77 | KMT2A (0.56) | MEN1KMT2A | |
| SCHEMBL20314566 | 0.77 | KDM2B (0.42) | DRD4 | |
| SCHEMBL1779090 | 0.76 | CCR2 (0.56) | CCR2KCNH2CYP3A4CYP2D6DRD2 | |
| SCHEMBL20436941 | 0.76 | KDM2B (0.49) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| CN-101384582-A | Piperazine compounds useful as antagonists of C-C chemokines (CCR2B and CCR5) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | CN | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2007071952-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | CCR2, CCR5, CCL2 | CCR2 1/4885KCNH2 1735/4885MEN1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.